Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly.

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI ...

LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous ...

Adaptability serves as the foundation for lasting career success, shaping leaders who can thrive in an ever-changing business ...

Then: In the May 2023 issue of Life Science Leader, Bobak Azamian, MD, Ph.D., cofounder and CEO of Tarsus Pharmaceuticals, talked about the company’s formation in 2016, and the decision to focus on ...

Falsified medicines are fakes that get into the supply chain, often via the Internet. These could be tablets or injectables that have the wrong amount of the right drug, with a dose that is too low or ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...

Life Science Leader is part of the Life Science Connect network of products and services for life science professionals. Life Science Connect’s vision is to facilitate connections and foster ...